Wegovy: A Promising Weight Loss Drug for Relieving Heart Failure Symptoms
A study funded by Novo Nordisk, the maker of the weight loss drug Wegovy, found that the drug eased symptoms and improved the quality of life for patients with obesity and a common type of heart failure known as preserved ejection fraction. The study showed that patients given Wegovy experienced greater improvements in physical fitness and heart failure symptoms compared to those given a placebo. The drug also showed more pronounced relief of heart failure symptoms than other treatments. The findings suggest that obesity should be treated as a root cause of heart failure and targeted as a therapeutic strategy. Further studies are needed to determine the long-term benefits and effects of the drug.
- Wegovy, the Weight Loss Drug, Relieves Heart Failure Symptoms: Drugmaker’s Study The New York Times
- Weight-loss drug Wegovy produces ‘largest benefit ever seen’ for patients with most common form of heart failure, trial finds CNN
- Weight-loss drug can reverse heart failure symptoms, study finds The Guardian
- Wegovy, Ozempic can help with heart failure symptoms, study finds New York Post
- Wegovy helps reduce heart failure symptoms in obese people, study says CNBC
Reading Insights
0
0
4 min
vs 5 min read
87%
859 → 114 words
Want the full story? Read the original article
Read on The New York Times